BioMin®’s clinically-proven Sensitivity Toothpaste on track for relaunch

Certification strengthens BioMin®’s commitment to clinically-led, science-backed oral care.

BioMin® is preparing to return to the UK and European market following certification under the European Medical Device Regulation (MDR), marking an important milestone for the company and the next chapter for its clinically-proven bioactive oral care technology. The new regulatory framework provides an enhanced level of scrutiny around clinical evidence, quality management, product safety and post-market surveillance. For BioMin®, the certification reinforces the clinical and scientific foundations on which the brand was built, while giving dental professionals and patients additional confidence in the quality, safety and performance of its products.

Built on decades of award-winning research at Queen Mary University of London, BioMin® was invented by Professor Robert Hill with collaboration from other departments at Queen Mary including Professor David Gillam. Its proprietary bioactive glass technology is internationally recognised for its clinically proven sensitivity relief and the strengthening of weakened enamel, and is a true innovation in advanced oral care.

BioMin®’s return-to-market strategy will focus on clinically-led educational content, including professional webinars, educational video series and evidence-based resources to support dental professionals. This will be retained alongside BioMin®’s wider growth strategy, including technology licensing, and the expansion of strategic partnerships.

BioMin® CEO Alec Hilton commented:

“Achieving MDR certification marks an important milestone for BioMin®. We have taken the time to do things properly, meeting the regulatory requirements while strengthening the systems and evidence that underpin our technology. For dental professionals and patients, this provides additional confidence in BioMin®’s quality, safety and clinical foundations, while giving us a strong platform for our return to market and future growth.”

BioMin®’s responsive, controlled-release technology continues to protect teeth for up to 12 hours after brushing through the sustained release of calcium, high phosphate and 530 ppm fluoride. These minerals form acid-resistant fluorapatite, progressively occluding exposed dentine tubules to relieve sensitivity while strengthening weakened enamel. Under acid challenge, BioMin® responds with enhanced mineral release and helps raise local pH, creating more favourable conditions for continued mineral deposition and remineralisation. This sustained delivery and ultra-fine particles provide effective, long-lasting protection using optimised levels of fluoride.

Prof Robert Hill, founder of BioMin®, said:

“BioMin®’s therapeutic benefits go above and beyond traditional toothpastes. Most of the fluoride in conventional toothpaste is washed away by salivary flow in the mouth, whereas BioMin® F Sensitivity releases fluoride gradually.”

“In the UK, almost half of adults suffer with sensitivity and a third of children have tooth decay. Bringing BioMin back to market with a new strategy it will allow us to supply our product to a far wider market, helping more people to repair and protect their teeth with our award-winning science-backed technology.”

Beyond toothpaste, during 2026, BioMin® has extended its role in preventive dentistry through collaboration. Its partnership with VOCO has resulted in VOCO Profluorid® Varnish + BioMin®, the first fluoride varnish to incorporate BioMin®’s bioactive glass technology, expanding its application into professional in-practice care, with further developments and additional collaborations to come in the years ahead.

With MDR certification achieved and a clear return-to-market strategy in place, BioMin® enters its next chapter focused on advancing prevention, supporting dental professionals and delivering lasting, science-led outcomes for patients.

Find out more about BioMin® by visiting the website and contacting the team.